252 related articles for article (PubMed ID: 22074610)
1. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
Hoomans T; Severens JL; van der Roer N; Delwel GO
Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
Hoomans T; van der Roer N; Severens JL; Delwel GO
Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
[TBL] [Abstract][Full Text] [Related]
3. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
[TBL] [Abstract][Full Text] [Related]
4. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
5. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
Yong JH; Beca J; Hoch JS
Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
[TBL] [Abstract][Full Text] [Related]
6. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
Anis AH; Rahman T; Schechter MT
Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
[TBL] [Abstract][Full Text] [Related]
7. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
Delwel GO; Sprenger MJ
Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
[TBL] [Abstract][Full Text] [Related]
8. Do reassessments reduce the uncertainty of decision making? Reviewing reimbursement reports and economic evaluations of three expensive drugs over time.
Sandmann FG; Franken MG; Steenhoek A; Koopmanschap MA
Health Policy; 2013 Oct; 112(3):285-96. PubMed ID: 23628483
[TBL] [Abstract][Full Text] [Related]
9. Penny and pound wise: pharmacoeconomics from a governmental perspective.
van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H
Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004
[TBL] [Abstract][Full Text] [Related]
10. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
11. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.
Cleemput I; van Wilder P; Huybrechts M; Vrijens F
Value Health; 2009 Jun; 12(4):441-9. PubMed ID: 19900251
[TBL] [Abstract][Full Text] [Related]
12. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
13. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
Franken M; Koopmanschap M; Steenhoek A
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
[TBL] [Abstract][Full Text] [Related]
14. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
[TBL] [Abstract][Full Text] [Related]
15. Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.
Cerri KH; Knapp M; Fernandez JL
Eur J Health Econ; 2014 Sep; 15(7):681-95. PubMed ID: 23864365
[TBL] [Abstract][Full Text] [Related]
16. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
Anis AH; Gagnon Y
Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
[TBL] [Abstract][Full Text] [Related]
17. Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results-Cost-Effectiveness and Budget Impact Analyses.
Ornstova E; Sebestianova M; Mlcoch T; Lamblova K; Dolezal T
Value Health Reg Issues; 2018 Sep; 16():92-98. PubMed ID: 30316030
[TBL] [Abstract][Full Text] [Related]
18. Reimbursement of targeted cancer therapies within 3 different European health care systems.
Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of drugs and its potential uses in policy making.
Johannesson M
Pharmacoeconomics; 1995 Sep; 8(3):190-8. PubMed ID: 10172485
[TBL] [Abstract][Full Text] [Related]
20. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies.
Vondeling H; Iversen PB
Eur J Health Econ; 2004 Oct; 5(3):263-9. PubMed ID: 15714347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
